White papers and other resources

September 3, 2024
White Paper
Genialis™ krasID White Paper
February 10, 2024
White Paper
RNA: the Future of Predictive Biomarkers
December 13, 2023
Tutorial
Normalizing RNA-seq data in Python with RNAnorm

Scientific journals

February 19, 2024
European Journal of Pharmaceutical Sciences
Transcriptome analysis reveals involvement of thiopurine S-methyltransferase in oxidation-reduction processes
May 23, 2023
Frontiers in Oncology
Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers
December 1, 2022
Journal of Personalized Medicine
Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience
May 17, 2022
Journal of Clinical Oncology
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Conference posters

September 25, 2024
RAS-Targeted Drug Development Summit 2024
Genialis™ krasID: Biology-driven Machine Learning to Personalize KRAS Inhibitor Therapy
April 9, 2024
AACR 2024
Genialis™ krasID: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapy
December 7, 2023
SABC 2023
Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in triple negative breast cancer patients
November 3, 2023
SITC 2023
Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in colorectal cancer patients
November 3, 2023
SITC 2023
Profiling microsatellite instability using RNA sequencing data
September 21, 2023
5th Annual RAS-Targeted Drug Development Summit 2023
ResponderID™ KRAS: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapeutics
June 13, 2023
EACR 2023
Evaluation of a KRAS gene expression signature in lung cancer
April 17, 2023
AACR 2023
The Xerna™ TME Panel potentially predicts response to a combination of the TLR9 agonist vidutolimod and PD-1 inhibitor pembrolizumab in metastatic melanomas with prior anti-PD-1 treatment